Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Science"
DOI: 10.1111/cas.13404
Abstract: This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with… read more here.
Keywords: personalized peptide; upper tract; metastatic upper; treatment ... See more keywords
Real‐World Outcomes of First‐Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study)
Sign Up to like & getrecommendations! Published in 2025 at "International Journal of Urology"
DOI: 10.1111/iju.70136
Abstract: To investigate the impact of renal impairment (RI) on the efficacy of first‐line chemotherapy in patients with locally advanced or metastatic upper tract urothelial carcinoma (la/mUTUC). read more here.
Keywords: tract urothelial; metastatic upper; first line; renal impairment ... See more keywords
Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.796407
Abstract: Urothelial carcinoma is the most common primary upper tract urinary carcinoma. If surgery, chemotherapy, and immunotherapy fail, the prognosis for upper tract urinary carcinoma is extremely poor. Immunotherapy combined with antiangiogenesis therapy is a new… read more here.
Keywords: pembrolizumab; toripalimab combined; metastatic upper; carcinoma ... See more keywords